MX2012013023A - Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. - Google Patents

Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.

Info

Publication number
MX2012013023A
MX2012013023A MX2012013023A MX2012013023A MX2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A
Authority
MX
Mexico
Prior art keywords
venlafaxine
extended release
alcohol
dosage forms
release dosage
Prior art date
Application number
MX2012013023A
Other languages
English (en)
Spanish (es)
Inventor
Ehab Hamed
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of MX2012013023A publication Critical patent/MX2012013023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2012013023A 2010-05-11 2011-05-09 Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. MX2012013023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33352710P 2010-05-11 2010-05-11
PCT/US2011/035768 WO2011143119A1 (en) 2010-05-11 2011-05-09 Alcohol-resistant extended release dosage forms comprising venlafaxine

Publications (1)

Publication Number Publication Date
MX2012013023A true MX2012013023A (es) 2012-12-17

Family

ID=44461928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013023A MX2012013023A (es) 2010-05-11 2011-05-09 Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.

Country Status (6)

Country Link
US (1) US20130171256A1 (enExample)
EP (1) EP2579857A1 (enExample)
JP (1) JP2013526522A (enExample)
CA (1) CA2798701A1 (enExample)
MX (1) MX2012013023A (enExample)
WO (1) WO2011143119A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3164117T3 (da) 2014-07-03 2023-12-04 SpecGx LLC Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
IN2003MU00504A (enExample) * 2003-06-05 2005-05-13 Alembic Ltd
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DK2200593T5 (en) * 2007-09-13 2016-12-12 Cima Labs Inc Hog-resistant pharmaceutical formulation

Also Published As

Publication number Publication date
CA2798701A1 (en) 2011-11-17
WO2011143119A1 (en) 2011-11-17
US20130171256A1 (en) 2013-07-04
JP2013526522A (ja) 2013-06-24
EP2579857A1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
MX2012013021A (es) Formulaciones resistentes a alcohol.
WO2011106416A3 (en) Abuse-resistant formulations
NZ600640A (en) Abuse-resistant formulations
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
IL199554B (en) Cyclopamine-like compounds and their use for the preparation of anti-proliferative drugs
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
MX345777B (es) Formulaciones de tabletas bicapa.
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
EP2665471A2 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
UA112764C2 (uk) Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
IL218008A (en) Dexbinol or its salt for non-melanoma cancer suppression, its use in the preparation of non-melanoma cancer suppressant, and a pharmacological preparation containing the said
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
NZ712159A (en) Antiemetic extended release solid dosage forms
PL2168584T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację triazolobenzodiazepiny i selektywnego inhibitora wychwytu zwrotnego serotoniny
HK1182030A (en) Alcohol-resistant extended release dosage forms comprising venlafaxine
HK1182014A (en) Alcohol-resistant metoprolol-containing extended- release oral dosage forms
WO2012111961A3 (ko) 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
HK1182013A (en) Alcohol-resistant formulations